144P A personalised sequencing approach for liquid biopsy-based detection of recurrent disease in early-stage breast cancer

Abstract

Currently, routine surveillance after primary therapy of early Breast cancer (BrCa) is limited to breast imaging. Follow up surveillance using circulating tumour DNA (ctDNA) for the detection of molecular residual disease is a useful tool to identify patients who may eventually develop distant metastases and holds promise for earlier intervention and improved overall survival. However, genomic alternations in breast cancer are very heterogeneous and follow-up surveillance requires ultrasensitive ctDNA assays.